CTRI/2012/07/002817已完成4 期
A randomised, double-blind, double-dummy, active-comparator controlledstudy investigating the efficacy and safety of linagliptin co-administeredwith metformin QD at evening time versus metformin BID over 14 weeks in treatment naive patients with type 2 diabetes mellitus andinsufficient glycaemic control.
Boehringer Ingelheim Pharmaceuticals0 个研究点目标入组 680 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 680
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All patients must sign and date an Informed Consent Form consistent with International
- •Conference on Harmonisation Good Clinical Practice guidelines and local legislation prior to participation in the trial that is prior to any trial procedure.
- •Male and female patients on diet and exercise regimen who are drug-naïve, defined as
- •absence of any oral antidiabetic drugs or any injectable antidiabetic therapies for at least 12 weeks prior to randomization.
- •HbA1c of ô???7.0% (53 mmol/mol)and ô???10.0% (86 mmol/mol)at Visit 1 i.e screening.
- •Age ô???18 and ô???65 years at Visit 1
- •BMI ô???45 kg/m2 (Body Mass Index) at Visit 1
排除标准
- •Uncontrolled hyperglycaemia with a glucose level 240 mg/dl (13.3mmol/L) after an overnight fast during screening/placebo run-in and confirmed by a second measurement (Not on the same day)
- •Treatment with any oral antidiabetic drug or insulin within 12 weeks prior to randomisation
- •Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent
- •Indication of liver disease / Impaired hepatic function , defined by serum levels of
- •either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening and/or run-in phase
- •Impaired renal function, defined as eGFR60 ml/min ( MDRD formula) as determined during screening or run-in phase.
- •Bariatric surgery within the past two years and other gastrointestinal surgeries that
- •induce chronic malabsorption.
- •Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
- •Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cell (e.g.
- •malaria, babesiosis, haemolytic anaemia)
- •Known history of pancreatitis and chronic pancreatitis.
- •Contraindications to metformin according to the local label.
- •Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen in the discretion of investigators, etc.) leading to unstable body weight.
- •Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM.
- •Pre-menopausal women (last menstruation <= 1 year prior to informed consent) who:
- •a. are nursing or pregnant or
- •b. are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during
- •participation in the trial or who do not agree to continue contraception for at least 30 days after the last dose of study drug. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives,complete sexual abstinence (if acceptable by local authorities), double barrier
- •method and vasectomised partner.
- •Alcohol or drug abuse in the discretion of investigators within the 3 months prior to
- •informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake.
- •Participation in another trial with application of any investigational drug within 30
- •days prior to informed consent.
- •Any other clinical condition that would jeopardize patients safety while participating
- •in this clinical trial according to investigatorâ??s judgement.
研究者
相似试验
进行中（未招募）
不适用
Dose finding study on BI54903 (inhaled corticosteroid) administered twice daily via Respimat® inhaler in asthmatic patients inadequately controlled on medium dose ICS therapy.AsthmaEUCTR2010-023169-23-DEBoehringer Ingelheim Pharma GmbH & Co. KG755
进行中（未招募）
1 期
Dose finding study on BI54903 (inhaled corticosteroid) administered twice daily via Respimat® inhaler in asthmatic patients inadequately controlled on medium dose ICS therapy.MedDRA version: 14.0Level: LLTClassification code 10003561Term: Asthma, unspecifiedSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2010-023169-23-BGBoehringer Ingelheim Pharma GmbH & Co. KG755
进行中（未招募）
1 期
Dose finding study on BI54903 (inhaled corticosteroid) administered twice daily via Respimat® inhaler in asthmatic patients inadequately controlled on medium dose ICS therapy.AsthmaEUCTR2010-023169-23-FRBoehringer Ingelheim Pharma GmbH & Co. KG755
进行中（未招募）
1 期
Dose finding study on BI54903 (inhaled corticosteroid) administered twice daily via Respimat® inhaler in asthmatic patients inadequately controlled on medium dose ICS therapy.MedDRA version: 14.0Level: LLTClassification code 10003561Term: Asthma, unspecifiedSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2010-023169-23-SKBoehringer Ingelheim Pharma GmbH & Co. KG755
已完成
2 期
A randomized, double-blind, double-dummy, active-controlled, multicenter, 2-part Phase II study on replacement of steroids by IFX-1 in active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)10047066NL-OMON55826InflaRx GmbH20